Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Midwife, a dream job

After her son was born, Lea Zerbe decided to become a midwife and enrolled in a training program at Helios Mariahilf Hospital in Hamburg.
Read the story
In battle against the coronavirus

Fresenius is taking comprehensive measures to ensure healthcare is available for patients during the COVID-19 pandemic.
Read the story
My 50 years of dialysis

I am Susanne Williams from Adelaide. I am 66 years old – and this is my story of 50 years of dialysis.
Read the story
Growing up with parenteral nutrition

How two brave adventurers from Switzerland are exploring the world step-by-step.
Read the story

News

Fresenius with solid H1 results – Accelerated earnings growth expected in H2 – New FY/20 guidance including COVID-19 effects

Stephan Sturm, CEO of Fresenius, said:”Particularly during the COVID-19 pandemic, Fresenius continues to make many important contributions to the provision of high-quality, affordable healthcare. In this way, we are standing with our patients around the world – and fulfilling our social responsibility. (...)"
July 30, 2020Fresenius
Fresenius Medical Care delivers very strong second quarter results

Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: “As anticipated, we saw the COVID-19 pandemic spread globally in the second quarter and continue to rise in Latin America and the U.S. In this challenging environment, the wide-ranging measures we took at a very early stage to ensure the continuity ...
July 30, 2020Fresenius Medical Care
Brief News
Curalie cooperates with ‘Wir für Gesundheit‘ and Debeka

The Berlin-based digital health company Curalie, a subsidiary of the Fresenius healthcare group, has entered a cooperation agreement with the “Wir für Gesundheit” quality medical care network and the health insurer Debeka. In the first step, a prevention app through which regular medical check-ups can be carried out, along with other functions, will be added to PlusCard. A supplementary company health insurance that companies can offer to their employees, PlusCard was jointly developed by “Wir für Gesundheit” and Debeka and has been offered since 2014. Additional digital components are planned for the prevention app, including a telemedicine function for the care of chronically ill patients.

July 29, 2020Fresenius

Fresenius Medical Care in Schweinfurt joins environmental pact of Germany’s Bavaria state

July 14, 2020Fresenius Medical Care
Brief News
Fresenius Helios publishes sustainability report

Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals, the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

July 08, 2020Fresenius Helios

Fresenius holds virtual General Meeting on August 28, 2020 – dividend proposal unchanged

July 08, 2020Fresenius
Fresenius Medical Care holds virtual General Meeting on August 27, 2020 – dividend proposal unchanged

July 08, 2020Fresenius Medical Care

Dr. Sebastian Biedenkopf to succeed Dr. Jürgen Götz on Management Board of Fresenius

June 23, 2020Fresenius
Brief News
Fresenius Medical Care expands TCU network in the USA

Fresenius Medical Care North America intends to open more than 100 new transitional care units (TCUs) this year. These units will help people recently diagnosed with kidney failure learn about the treatment options available to them including home dialysis, and become more empowered in managing their own care. TCUs are designed to be a separate space within a dialysis center with staff dedicated to onboarding patients new to dialysis during their first weeks of treatment, assisting patients transitioning between modalities, and supporting individuals returning to dialysis from transplant. Fresenius Medical Care North America has been rapidly opening TCUs, with a total of 65 operating already, in support of its home growth strategy. The company has found that over 50 percent of TCU patients will choose a home dialysis modality.

June 19, 2020Fresenius Medical Care

Fresenius Medical Care expands production at St. Wendel plant in response to higher demand caused by COVID-19 pandemic

June 15, 2020Fresenius Medical Care
Brief News
Drug from Fresenius Kabi now available in the U.S. after Emergency Use Authorization

Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

June 15, 2020Fresenius Kabi

Fresenius Helios acquires hospital in western Germany

May 29, 2020Fresenius Helios
Brief News
Fresenius Kabi enters marketing agreement for biosimilar product

Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

May 28, 2020Fresenius Kabi

Brief News
Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by FDA

Fresenius Kabi announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company`s Biologics License Application (BLA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is an important achievement in the development of Fresenius Kabi’s biosimilar pipeline in the US. Fresenius Kabi also received acceptance for review of its regulatory submission for its pegfilgrastim biosimilar candidate from the European Medicines Agency this month. (* Neulasta® is a registered trademark of Amgen)

May 27, 2020Fresenius Kabi
Brief News
Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA

The European Medicines Agency (EMA) has accepted for review Fresenius Kabi`s Marketing Authorization Application (MAA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is another milestone for Fresenius Kabi following last year`s approval and launch of the company`s adalimumab biosimilar (Idacio®) in Europe. (* Neulasta® is a registered trademark of Amgen)

May 22, 2020Fresenius Kabi

Fresenius Medical Care confirms illegal publication of patient data in Serbia subsequent to recent hacker attack

May 21, 2020Fresenius Medical Care
Fresenius Medical Care places bonds with a volume of 1.25 billion euros

May 19, 2020Fresenius Medical Care

Solid start to 2020 – Fresenius proves its resilience in light of significant COVID-19 effects

May 06, 2020Fresenius
Fresenius Medical Care posts solid first quarter results underlining resilience of business model

May 06, 2020Fresenius Medical Care

Fresenius Medical Care enhances home dialysis offering for patients in Europe, Middle East and Africa region

May 04, 2020Fresenius Medical Care
Brief News
Fresenius Medical Care supplies extra dialysis machines for COVID-19 patients in U.S.

Fresenius Medical Care North America is making 150 additional dialysis machines available to U.S. hospitals for the emergency treatment of COVID-19 patients, under the company’s newly established National Intensive Renal Care Reserve. The reserve creates a pool of dialysis machines that can be sent to hospitals on short notice, and nearly doubles the volume of consumables available to perform treatments. The increased demand is a result of many COVID-19 patients requiring renal replacement therapy due to acute kidney injury, and not all hospitals having enough dialysis machines to treat them.

April 22, 2020Fresenius Medical Care

Brief News
Fresenius Helios develops process for safe reuse of masks

Fresenius Helios has developed a secure and highly effective process for purifying medical protective masks so they can be safely reused. It is being employed for FFP2- and FFP3-type masks, which help protect medical and care personnel who are treating COVID-19 patients. Going well beyond the safety standard set out by the Robert Koch Institute, Germany’s government agency responsible for disease control and prevention, the process allows the purified masks to be used by any staff member – not just the previous user. Starting immediately, Helios Germany’s hospitals can purify 8,000 masks daily using the process, which was developed with the support of Fresenius Vamed and Fresenius Medical Care. The company has chosen not to commercialize the process and is making complete information about it available online, free of charge.

April 22, 2020Fresenius Helios
Brief News
Fresenius Helios supports COVID-19 research

To obtain and secure important data for research into SARS-CoV 2, Fresenius Helios has established a multi-center COVID-19 register. Since back in February a team of Helios experts, supported by the Brandenburg Medical School outside of Berlin, has been gathering pseudonymized data on patients treated for COVID-19 in Germany. The goal is to develop insights and knowledge for the battle against the new virus. First research findings from the project, which is scheduled to last a year and is financed by Helios, are now being readied for publication.

April 20, 2020Fresenius Helios

Fresenius Medical Care calls for kidney disease patients to have continued access to customary care level during COVID-19 crisis

April 09, 2020Fresenius Medical Care
Fresenius Kabi takes comprehensive measures to increase supply of essential drugs during COVID 19 pandemic

April 07, 2020Fresenius Kabi

Fresenius Medical Care partners with other dialysis providers to combat coronavirus pandemic in the U.S.

April 01, 2020Fresenius Medical Care
Fresenius successfully places bonds with a volume of 750 million euros

March 31, 2020Fresenius

Fresenius postpones 2020 Annual General Meeting

March 30, 2020Fresenius
Fresenius Medical Care postpones 2020 Annual General Meeting

March 30, 2020Fresenius Medical Care

Fresenius takes comprehensive measures to combat COVID 19 pandemic in Germany

March 27, 2020Fresenius Helios

Disclaimer All news

LATEST

July 30, 2020 - 01:30 PM | Bad Homburg, Germany

Conference Call Q2 2020, Fresenius

Live Webcast

Webcast Import (ICS) Investor News (PDF) Presentation (PDF) Podcast (MP3) Transcript (PDF)

LATEST

Library

All Downloads

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us